Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 11/20 | 1.00 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.55 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.55 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.55 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.52 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.52 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.50 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.50 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.50 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30011597 | 1.00 | HTR2C (1.00) | HTR2CHTR1ASLC6A2SLC6A4KDM1A | |
| SCHEMBL1513258 | 0.98 | HTR2C (1.00) | HTR2CHTR1ASLC6A2SLC6A4KDM1A | |
| SCHEMBL1810139 | 0.86 | HTR2C (0.79) | HTR2CHTR1ASLC6A2SLC6A4KDM1A | |
| SCHEMBL29890520 | 0.86 | HTR2C (0.79) | HTR2CHTR1ASLC6A2SLC6A4KDM1A | |
| Fluoride SCHEMBL28219231 | 0.85 | HTR2C (0.76) | HTR2CHTR1ASLC6A2SLC6A4KDM1A | |
| Hydrochloric Acid SCHEMBL21855666 | 0.85 | HTR2C (1.00) | HTR2CHTR1ASLC6A2SLC6A4HTR6 | |
| Hydrochloric Acid SCHEMBL31109384 | 0.85 | HTR2C (1.00) | HTR2CHTR1ASLC6A2SLC6A4HTR6 | |
| SCHEMBL30493303 | 0.83 | HTR2C (0.72) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1225741 | 0.83 | HTR2C (0.72) | HTR2CKDM1A | |
| SCHEMBL5584737 | 0.82 | HTR2C (1.00) | HTR2CHTR1ASLC6A2SLC6A4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-04 | — | — | US | disclosed |
| US-20240092781-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-21 | — | — | US | disclosed |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-17 | — | — | US | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | disclosed |
| EP-4126840-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| CN-115362151-A | Aryl piperidines as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2022-11-18 | — | — | CN | disclosed |
| US-20220363679-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | US | disclosed |
| WO-2021191384-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | WO | disclosed |
| EP-2206714-B1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| EP-1283199-A1 | MELANIN-CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
| EP-1278729-A1 | BENZOSUBERONYLPIPERIDINE COMPOUNDS AS ANALGESICS | GlaxoSmithKline S.p.A. (IT) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001083454-A1 | BENZOSUBERONYLPIPERIDINE COMPOUNDS AS ANALGESICS | GLAXOSMITHKLINE S.P.A. (IT) | 2001-11-08 | — | — | WO | disclosed |
| EP-1009405-A4 | PYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2001-05-09 | — | — | EP | disclosed |
| US-6166037-A | Pyrrolidine and piperidine modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-1009405-A1 | PYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999009984-A1 | PYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| US-4110459-A | ANALGESIC | AMERICAN HOECHST CORPORATION (US) | 1978-08-29 | — | — | US | disclosed |
| US-4101663-A | ANTIHYPERTENSIVES | AMERICAN HOECHST CORPORATION (US) | 1978-07-18 | — | — | US | disclosed |
| US-4046900-A | TRANQUILIZERS, HYPOTENSIVES, ANALGESICS | AMERICAN HOECHST CORPORATION (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092781-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | HTR2C 64/4885HTR1A 33/4885SLC6A2 1095/4885 |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | HTR2C 4530/4885HTR1A 4284/4885SLC6A2 4707/4885 |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | DGKK, DGKG, DGKA | HTR2C 4530/4885HTR1A 4284/4885SLC6A2 4707/4885 |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | HTR2C 64/4885HTR1A 33/4885SLC6A2 1095/4885 |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | HTR2C 4530/4885HTR1A 4284/4885SLC6A2 4707/4885 |
| US-20220363679-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | HTR2C 64/4885HTR1A 33/4885SLC6A2 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.